PPC
MCID: PRM126
MIFTS: 62

Primary Peritoneal Carcinoma (PPC)

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Primary Peritoneal Carcinoma

MalaCards integrated aliases for Primary Peritoneal Carcinoma:

Name: Primary Peritoneal Carcinoma 58 36 71
Serous Surface Papillary Carcinoma 58 71
Extra-Ovarian Primary Peritoneal Carcinoma 58
Primary Peritoneal Serous Adenocarcinoma 71
Primary Peritoneal Serous Carcinoma 58
Eoppc 58
Ppc 58

Characteristics:

Orphanet epidemiological data:

58
primary peritoneal carcinoma
Age of onset: Adult; Age of death: normal life expectancy;

Classifications:



External Ids:

KEGG 36 H01665
ICD10 via Orphanet 33 C48.2
Orphanet 58 ORPHA168829
UMLS 71 C0334361 C1514428 C1514429

Summaries for Primary Peritoneal Carcinoma

KEGG : 36 Female primary peritoneal carcinoma (PPC) has the characteristic of diffuse involvement of the peritoneum by papillary carcinoma in the absence of an obvious primary site and grossly normal ovaries, or minimal involvement. It is histologically indistinguishable from primary epithelial ovarian carcinoma (EOC) and is diagnosed in the absence of another identifiable primary. Most reported PPC cases are primary peritoneal serous papillary carcinoma (PPSPC), while peritoneal mixed epithelial carcinoma (MEC) and malignant mixed Mullerian tumor (MMMT) are rarely reported. Germline BRCA1 mutations in 26% of PPSPC patients was detected. BRCA1 mutation carriers had a higher overall incidence of p53 mutations than wildtype BRCA1 case subjects. It is suggested that p53 has a unique role in the development and progression of BRCA1-related PPSPC.

MalaCards based summary : Primary Peritoneal Carcinoma, also known as serous surface papillary carcinoma, is related to familial ovarian cancer and stomatitis. An important gene associated with Primary Peritoneal Carcinoma is BRCA1 (BRCA1 DNA Repair Associated), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Alvimopan and Tamoxifen have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and endothelial, and related phenotypes are nausea and vomiting and abdominal pain

Wikipedia : 74 Primary peritoneal cancer or carcinoma is also known as serous surface papillary carcinoma, primary... more...

Related Diseases for Primary Peritoneal Carcinoma

Diseases related to Primary Peritoneal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 432)
# Related Disease Score Top Affiliating Genes
1 familial ovarian cancer 30.4 BRCA2 BRCA1
2 stomatitis 30.3 IL10 IFNG CXCL8
3 inflammatory breast carcinoma 30.1 PGR ERBB2 EGFR
4 neutropenia 29.8 TP53 IL10 IFNG CXCL8
5 prostatitis 29.8 TP53 IL10 CXCL8
6 glioma 29.6 TP53 ERBB2 EGFR BRCA2
7 peritonitis 29.5 MUC16 IL10 IFNG CXCL8
8 diarrhea 29.4 IL10 IFNG ERBB2 EGFR CXCL8
9 exanthem 29.3 VEGFA IL10 IFNG ERBB2 EGFR CXCL8
10 carcinosarcoma 29.3 TP53 PGR ERBB2 EGFR
11 hereditary breast ovarian cancer syndrome 29.3 TP53 ERBB2 BRCA2 BRCA1
12 papillary serous adenocarcinoma 29.3 TP53 PGR BRCA2 BRCA1
13 thrombocytopenia 29.2 IL10 IFNG ERBB2 CXCL8 CXCL10
14 ovarian cystadenocarcinoma 28.9 TP53 MUC16 ERBB2 EGFR BRCA2 BRCA1
15 fallopian tube carcinoma 28.7 VEGFA TP53 PGR ERBB2 BRCA2 BRCA1
16 adenocarcinoma 28.4 VEGFA TP53 RET ERBB2 EGFR BRCA2
17 in situ carcinoma 28.4 TP53 PGR ERBB2 EGFR BRCA2 BRCA1
18 peripheral nervous system disease 28.4 VEGFA TP53 IL10 IFNG ERBB2 CXCL8
19 endometriosis 28.4 VEGFA TP53 PGR MUC16 CXCL8
20 cystadenocarcinoma 28.3 VEGFA TP53 PGR MUC16 ERBB2 BRCA1
21 dilated cardiomyopathy 28.3 VEGFA TP53 IL10 IFNG ERBB2 EGFR
22 eye disease 28.2 VEGFA TP53 IL10 IFNG CXCL8 CXCL10
23 serous cystadenocarcinoma 27.9 VEGFA TP53 PGR MUC16 ERBB2 BRCA2
24 ovary epithelial cancer 27.6 VEGFA TP53 PGR MUC16 ERBB2 EGFR
25 malignant ovarian surface epithelial-stromal neoplasm 27.6 VEGFA TP53 PGR MUC16 ERBB2 EGFR
26 ovary adenocarcinoma 27.3 VEGFA TP53 PGR MUC16 ERBB2 EGFR
27 ovarian disease 27.3 VEGFA TP53 PGR MUC16 ERBB2 EGFR
28 endometrial cancer 26.6 VEGFA TP53 RET PGR MUC16 ERBB2
29 ovarian cancer 26.3 VEGFA TP53 PGR MUC16 MIR195 IL10
30 lung cancer 25.4 VEGFA TP53 RET MUC16 MIR497 MIR195
31 ovary papillary carcinoma 11.6
32 fallopian tube clear cell adenocarcinoma 10.6 BRCA2 BRCA1
33 rare malignant breast tumor 10.6 BRCA2 BRCA1
34 ovary transitional cell carcinoma 10.5 BRCA2 BRCA1
35 hereditary site-specific ovarian cancer syndrome 10.5 BRCA2 BRCA1
36 tetraploidy 10.5 BRCA2 BRCA1
37 cancerophobia 10.5 BRCA2 BRCA1
38 nosophobia 10.5 BRCA2 BRCA1
39 recurrent respiratory papillomatosis 10.4 ERBB2 EGFR
40 breast juvenile papillomatosis 10.4 ERBB2 BRCA2
41 breast-ovarian cancer, familial 2 10.4 BRCA2 BRCA1
42 acute transverse myelitis 10.4 IL10 CXCL8
43 ovarian epithelial cancer 10.4
44 prostatic hypertrophy 10.4
45 fuchs' heterochromic uveitis 10.4 IFNG CXCL8
46 spotted fever rickettsiosis 10.4 IL10 IFNG
47 neurosyphilis 10.3 IL10 CXCL8 CXCL10
48 glassy cell carcinoma of the cervix 10.3 PGR ERBB2
49 pleural tuberculosis 10.3 IFNG CXCL8 CXCL10
50 chronic graft versus host disease 10.3 IL10 IFNG

Graphical network of the top 20 diseases related to Primary Peritoneal Carcinoma:



Diseases related to Primary Peritoneal Carcinoma

Symptoms & Phenotypes for Primary Peritoneal Carcinoma

Human phenotypes related to Primary Peritoneal Carcinoma:

58 31 (show all 6)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 58 31 hallmark (90%) Very frequent (99-80%) HP:0002017
2 abdominal pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0002027
3 neoplasm 58 31 hallmark (90%) Very frequent (99-80%) HP:0002664
4 constipation 58 31 hallmark (90%) Very frequent (99-80%) HP:0002019
5 abdominal distention 58 31 hallmark (90%) Very frequent (99-80%) HP:0003270
6 peritonitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002586

MGI Mouse Phenotypes related to Primary Peritoneal Carcinoma:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.36 BRCA1 BRCA2 CXCL10 EGFR ERBB2 ERCC1
2 embryo MP:0005380 10.31 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
3 homeostasis/metabolism MP:0005376 10.31 BRCA1 BRCA2 CXCL10 EGFR ERBB2 ERCC1
4 endocrine/exocrine gland MP:0005379 10.3 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
5 cardiovascular system MP:0005385 10.29 BRCA1 CXCL10 EGFR ERBB2 IFNG IL10
6 hematopoietic system MP:0005397 10.29 BRCA1 BRCA2 CXCL10 EGFR ERCC1 IFNG
7 immune system MP:0005387 10.26 BRCA1 BRCA2 CXCL10 EGFR ERCC1 IFNG
8 mortality/aging MP:0010768 10.26 BRCA1 BRCA2 CXCL10 EGFR ERBB2 ERCC1
9 digestive/alimentary MP:0005381 10.23 BRCA1 BRCA2 EGFR ERBB2 IFNG IL10
10 integument MP:0010771 10.21 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
11 neoplasm MP:0002006 10.17 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
12 muscle MP:0005369 10.16 BRCA1 EGFR ERBB2 ERCC1 IFNG IL10
13 limbs/digits/tail MP:0005371 10.15 BRCA1 BRCA2 EGFR ERBB2 IL10 PGR
14 nervous system MP:0003631 10.14 BRCA1 BRCA2 CXCL10 EGFR ERBB2 ERCC1
15 normal MP:0002873 10.02 BRCA1 BRCA2 EGFR ERBB2 IFNG IL10
16 no phenotypic analysis MP:0003012 9.91 EGFR IFNG IL10 PGR RET TP53
17 reproductive system MP:0005389 9.9 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
18 renal/urinary system MP:0005367 9.8 BRCA1 EGFR ERCC1 IFNG RET TP53
19 respiratory system MP:0005388 9.56 BRCA1 EGFR ERBB2 IFNG IL10 RET
20 skeleton MP:0005390 9.32 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG

Drugs & Therapeutics for Primary Peritoneal Carcinoma

Drugs for Primary Peritoneal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
2
Tamoxifen Approved Phase 3 10540-29-1 2733526
3
Sodium citrate Approved, Investigational Phase 3 68-04-2
4
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
5
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
6
Gemcitabine Approved Phase 3 95058-81-4 60750
7
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
8
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
9
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
10 Hormone Antagonists Phase 3
11 Hormones Phase 3
12 Antineoplastic Agents, Hormonal Phase 3
13 Estrogen Receptor Modulators Phase 3
14 Estrogen Antagonists Phase 3
15 Estrogen Receptor Antagonists Phase 3
16 Estrogens Phase 3
17 Citrate Phase 3
18 Antineoplastic Agents, Immunological Phase 3
19 Angiogenesis Inhibitors Phase 3
20 Tubulin Modulators Phase 3
21 Antimitotic Agents Phase 3
22 Immunoglobulins Phase 3
23 Antibodies Phase 3
24 Mitogens Phase 3
25 Antibodies, Monoclonal Phase 3
26 Immunologic Factors Phase 3
27 Immunoglobulins, Intravenous Phase 3
28 Endothelial Growth Factors Phase 3
29 Immunoglobulin G Phase 3
30
Liposomal doxorubicin Phase 3 31703
31 Albumin-Bound Paclitaxel Phase 3
32 Anti-Infective Agents Phase 3
33 Antiviral Agents Phase 3
34 interferons Phase 3
35 Interferon-gamma Phase 3
36
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
37
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
38
Pemetrexed Approved, Investigational Phase 2 137281-23-3, 150399-23-8 60843 446556
39
leucovorin Approved Phase 2 58-05-9 6006 143
40
ramucirumab Approved, Investigational Phase 2 947687-13-0
41
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
42
Ketoconazole Approved, Investigational Phase 1, Phase 2 65277-42-1 47576
43
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
44
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
45
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
46
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
47
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
48
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
49
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
50
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353

Interventional clinical trials:

(show top 50) (show all 136)
# Name Status NCT ID Phase Drugs
1 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial. Unknown status NCT02328716 Phase 3 Hipec with Cisplatin
2 Accelerating Gastrointestinal Recovery in Women Undergoing Staging and/or Debulking Surgery for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial Completed NCT01704651 Phase 3 Alvimopan;Placebo
3 Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
4 A Phase III Randomized Trial Of Paclitaxel And Carboplatin Versus Triplet Or Sequential Doublet Combinations In Patients With Epithelial Ovarian Or Primary Peritoneal Carcinoma Completed NCT00011986 Phase 3 Paclitaxel;Carboplatin;Gemcitabine Hydrochloride;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
5 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
6 A Randomized Study Of Tamoxifen Versus Thalidomide (NSC# 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer Of The Fallopian Tube, And Primary Peritoneal Carcinoma After First Line Chemotherapy Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
7 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
8 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
9 A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of DCVAC/OvCa Added to Standard of Care in Patients With Relapsed Platinum-sensitive Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Not yet recruiting NCT03905902 Phase 3
10 Interferon Gamma-1b in Combination With Chemotherapy (Carboplatin/Paclitaxel) for First Line Therapy of Advanced Ovarian or Primary Peritoneal Carcinoma. Terminated NCT00047632 Phase 3 Interferon gamma-1b
11 A Phase II Study of Docetaxel and Carboplatin for Suboptimally Debulked Stage III or Stage IV Ovarian and Fallopian Tube Carcinoma Unknown status NCT00003560 Phase 2 carboplatin;docetaxel
12 Use of Changes in CA 125 Doubling Time to Detect Activity of Cytostatic Agents in Women Relapsing With Ovarian Carcinoma. Study 1-Tamoxifen Unknown status NCT00305838 Phase 2 tamoxifen citrate
13 A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
14 Phase II Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer (CRAD001CUS242T) Unknown status NCT02188550 Phase 2 everolimus and letrozole
15 Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian and Primary Peritoneal Carcinoma Completed NCT00868192 Phase 2 Pemetrexed;Bevacizumab
16 A Phase II Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Carcinoma Completed NCT00420381 Phase 2 enzastaurin
17 A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00721162 Phase 2
18 A Phase II Trial of Oral Capecitabine in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00004012 Phase 2 capecitabine
19 A Phase II Study of a Three-Day Schedule of Topotecan Plus Paclitaxel and Carboplatin on Day Three in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma Completed NCT00193297 Phase 2 Topotecan;Paclitaxel;Carboplatin
20 A Phase IIA Evaluation of Safety and Efficacy of Weekly S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Stage III or IV Platinum Resistant Ovarian Cancer or Primary Peritoneal Carcinoma Completed NCT00034151 Phase 2 S-8184 Paclitaxel Injectable Emulsion
21 Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT01535157 Phase 1, Phase 2 Fenretinide/LXS + Ketoconazole
22 Neoadjuvant Platinum-based Chemotherapy in Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Trial Protocol Completed NCT01519869 Phase 2 neoadjuvant chemotherapy
23 A Phase II Study of Sunitinib (SU11248; NSC 736511) in Patients With Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00388037 Phase 2 sunitinib malate
24 Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intraperitoneal Administration of DTA-H19 in Subjects With Advanced Stage Ovarian Cancer Completed NCT00826150 Phase 1, Phase 2
25 A Phase II Evaluation of BAY 43-9006 (Sorafenib, Nexavar®, NCI-Supplied Agent, NSC #724772) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Completed NCT00093626 Phase 2 Sorafenib Tosylate
26 A Multicenter Open Label Phase II Study of the Efficacy and Safety of AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) as Second Line Therapy in Patients With Recurrent Platinum Sensitive Ovarian Cancer Completed NCT00719212 Phase 2
27 A Phase II Evaluation of Pemetrexed (Alimta, LY231514l, IND # 40061) in the Treatment of Recurrent or Persistent Platinum Resistant Ovarian or Primary Peritoneal Carcinoma Completed NCT00461786 Phase 2 pemetrexed
28 A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients With Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00853307 Phase 2 Alisertib
29 A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT01381861 Phase 2
30 A Study to Evaluate Efficacy and Safety of Pazopanib Monotherapy in Asian Women Who Have Not Progressed After First-line Chemotherapy for Advanced Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma - An Extension Study to VEG110655 Completed NCT01227928 Phase 2 Pazopanib;Placebo comparator
31 Phase II Trial of Fenretinide (NSC 374551) in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00026091 Phase 2 fenretinide
32 A Phase II Trial of ZD1839 (Iressa) (NSC# 715055) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Completed NCT00023699 Phase 2 gefitinib
33 A Phase I/II Trial fo Intravenous CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00017017 Phase 1, Phase 2 paclitaxel poliglumex
34 Evaluation of Aminocamptothecin (9-AC, NSC #603071) in Recurrent, Platinum Resistant and Refractory Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00003523 Phase 2 aminocamptothecin colloidal dispersion
35 A Phase II Evaluation of Karenitecin in the Third-Line Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Completed NCT00054119 Phase 2 Cositecan
36 A Phase 2 Study of Bevacizumab With Abraxane in Patients With Recurrent, Platinum-Resistant Primary Epithelial Ovarian or Primary Peritoneal Carcinoma Completed NCT00407563 Phase 2 Bevacizumab;Abraxane
37 A Phase II Study of Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Epithelial Ovarian/Fallopian Tube/ Primary Peritoneal Carcinoma. Completed NCT01196559 Phase 2 Vinorelbine and Gemcitabine
38 A Multicenter, Single-Arm, Phase II Trial of Bevacizumab in Subjects With Platinum-Resistant Epithelial Carcinoma of the Ovary or Primary Peritoneal Carcinoma for Whom Subsequent Doxil or Topotecan Therapy Has Failed Completed NCT00097019 Phase 2 bevacizumab
39 Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid®) With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma Completed NCT00179712 Phase 1, Phase 2 CC-5013;topotecan
40 CT-2103/Carboplatin for Patients With Newly Diagnosed Stage III or IV Ovarian or Primary Peritoneal Cancer: A Phase 2 Study Completed NCT00069901 Phase 2 CT-2103 (poly(L)glutamate-paclitaxel);carboplatin
41 A Phase II Evaluation of AMG 102 (Rilotumumab) (NSC #750009) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT01039207 Phase 2
42 Phase II Clinical Trial of Bevacizumab (NSC 704865) and Low Dose Oral Cyclophosphamide in Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma Completed NCT00072566 Phase 2 Cyclophosphamide
43 Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen Completed NCT00112957 Phase 2
44 A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Suboptimally Debulked Stage III or IV Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
45 A Phase II Evaluation Of Gleevec (Imatinib Mesylate) (IND #61135, NSC #716051) In The Treatment Of Persistent Or Recurrent Epithelial Ovarian Or Primary Peritoneal Carcinoma Completed NCT00041041 Phase 2 imatinib mesylate
46 Phase II Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients With Peritoneal Carcinomatosis (Residual Disease < 1cm) Associated With Ovarian Epithelial Cancer or Primary Peritoneal Carcinoma Completed NCT00016289 Phase 2
47 A Phase II Evaluation of CCI-779 (Temsirolimus, NCI-Supplied Agent, NSC #683864, IND #61010) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00429793 Phase 2 temsirolimus
48 A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women With Newly Diagnosed, Previously Untreated, Gynaecological Tumors Completed NCT00561795 Phase 2 pazopanib (GW786034);carboplatin;paclitaxel
49 A Phase II Evaluation Of Pemetrexed (ALIMTA LY231514, IND #40061) In The Treatment Of Recurrent Or Persistent Platinum-Resistant Ovarian Or Primary Peritoneal Carcinoma Completed NCT00087087 Phase 2 pemetrexed disodium
50 Phase II Evaluation of Oxaliplatin in Recurrent, Platinum Resistant and Refractory Ovarian Cancer Completed NCT00005836 Phase 2 oxaliplatin

Search NIH Clinical Center for Primary Peritoneal Carcinoma

Genetic Tests for Primary Peritoneal Carcinoma

Anatomical Context for Primary Peritoneal Carcinoma

MalaCards organs/tissues related to Primary Peritoneal Carcinoma:

40
Ovary, Breast, Endothelial, Liver, Brain, Testes, Skin

Publications for Primary Peritoneal Carcinoma

Articles related to Primary Peritoneal Carcinoma:

(show top 50) (show all 332)
# Title Authors PMID Year
1
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. 61
32247603 2020
2
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). 61
32083163 2020
3
Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study. 61
32206654 2020
4
Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. 61
31986452 2020
5
Prognostic utility of FDG PET/CT in advanced ovarian, fallopian and primary peritoneal high-grade serous cancer patients before and after neoadjuvant chemotherapy. 61
31768818 2020
6
Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). 61
32337492 2020
7
Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas. 61
31699802 2020
8
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. 61
31791688 2019
9
Primary peritoneal carcinoma with late-phase pulmonary metastases: a case report. 61
31823088 2019
10
TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). 61
31420412 2019
11
A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. 61
31082382 2019
12
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. 61
31216226 2019
13
Removal of the entire internal iliac vessel system is a feasible surgical procedure for locally advanced ovarian carcinoma adhered firmly to the pelvic sidewall. 61
30891652 2019
14
Multifactorial impact on the outcome of interval debulking surgery in patients with advanced epithelial ovarian or peritoneal cancers. 61
30885671 2019
15
Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis from rare etiologies. 61
30760409 2019
16
TNM classification of gynaecological malignant tumours, eighth edition: changes between the seventh and eighth editions. 61
30668753 2019
17
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. 61
30587441 2019
18
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. 61
30522700 2019
19
Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients. 61
29782365 2019
20
Somatic variants of potential clinical significance in the tumors of BRCA phenocopies. 61
31346352 2019
21
A Patient Affected with Serous Ovarian/Peritoneal Carcinoma Carrying the FANCM Mutation. 61
31223512 2019
22
Case Report: Borderline tumor and primary peritoneal carcinoma - a rare synchronism. 61
31807285 2019
23
[A Case of Multiple Laparoscopic Surgeries Performed for Disseminated Peritoneal Recurrence of Primary Peritoneal Carcinoma]. 61
30692361 2018
24
Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study. 61
29623583 2018
25
Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. 61
30135020 2018
26
Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. 61
32136794 2018
27
Diagnostic and prognostic value of HE4 in female patients with primary peritoneal carcinoma. 61
30238835 2018
28
Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis. 61
29773661 2018
29
Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery? 61
29933927 2018
30
Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). 61
29739622 2018
31
Multicenter Clinicopathological Study of High-Grade Serous Carcinoma Presenting as Primary Peritoneal Carcinoma. 61
29324533 2018
32
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses. 61
29500276 2018
33
[A Case of Splenic Metastasis from Serous Surface Papillary Carcinoma of the Peritoneum Treated by Laparoscopic Splenectomy]. 61
29650839 2018
34
Outcome of elevated CA125 values from primary care following implementation of ovarian cancer guidelines. 61
29029123 2018
35
Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review. 61
29094253 2018
36
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. 61
29242937 2018
37
Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families? 61
29659587 2018
38
Cauda equina syndrome secondary to leptomeningeal metastases from recurrent primary peritoneal carcinoma. 61
29515655 2018
39
Management of Preinvasive Lesions. 61
28957950 2017
40
Serous Tubal Carcinogenesis: The Recent Concept of Origin of Ovarian, Primary Peritoneal and Fallopian Tube High-Grade Serous Carcinoma. 61
29162958 2017
41
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. 61
28698009 2017
42
Early-onset primary peritoneal carcinoma from atypical cells after risk-reducing salpingo-oophorectomy for BRCA2 mutation carrier: a case report. 61
31149481 2017
43
Brain metastasis from primary peritoneal carcinoma: Case report and literature review. 61
28279555 2017
44
Extraovarian Primary Peritoneal Carcinomatosis: A Case Report. 61
28649123 2017
45
Advanced Primary Epithelial Ovarian and Peritoneal Carcinoma-Does Diagnostic Accuracy of Preoperative CT Scan for Detection of Peritoneal Metastatic Sites Reflect into Prediction of Suboptimal Debulking? A Prospective Study. 61
28546700 2017
46
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. 61
28453702 2017
47
The diagnostic utility of PAX8 immunostaining of malignant peritoneal mesothelioma presenting as serous ovarian carcinoma: A single-center report of two cases. 61
28123552 2017
48
Clinical characteristics of primary peritoneal carcinoma patients: a single-institution experience involving 8 patients. 61
28008196 2016
49
Primary peritoneal carcinoma metastasizing to breast: a single case report and literature review from clinic to biology. 61
27807506 2016
50
Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes. 61
27261325 2016

Variations for Primary Peritoneal Carcinoma

Cosmic variations for Primary Peritoneal Carcinoma:

9 (show top 50) (show all 5397)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87898714 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.844C>T p.R282W 17:7673776-7673776 6
2 COSM87904406 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.796G>A p.G266R 17:7673824-7673824 6
3 COSM87913147 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.845G>A p.R282Q 17:7673775-7673775 6
4 COSM87967612 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.652G>A p.V218M 17:7674879-7674879 6
5 COSM87985048 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.830G>A p.C277Y 17:7673790-7673790 6
6 COSM87897904 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.596G>A p.G199E 17:7674935-7674935 6
7 COSM87985433 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.965C>T p.P322L 17:7673563-7673563 6
8 COSM88000728 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.673G>T p.V225F 17:7674290-7674290 6
9 COSM87910628 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.772G>A p.E258K 17:7674191-7674191 6
10 COSM87921224 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.835G>A p.G279R 17:7673785-7673785 6
11 COSM87902369 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.1009C>T p.R337C 17:7670700-7670700 6
12 COSM87906659 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.659A>C p.Y220S 17:7674872-7674872 6
13 COSM142560558 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.727C>T p.R243W 17:7673776-7673776 6
14 COSM122271411 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.200G>A p.G67E 17:7674935-7674935 6
15 COSM121876472 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.448C>T p.R150W 17:7673776-7673776 6
16 COSM143156843 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.266G>A p.R89Q 17:7674220-7674220 6
17 COSM111804340 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.755T>C p.L252P 17:7674208-7674208 6
18 COSM142647957 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.556G>T p.V186F 17:7674290-7674290 6
19 COSM105689382 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.652G>A p.V218M 17:7674879-7674879 6
20 COSM143158609 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.*131C>T p.? 17:7670685-7670685 6
21 COSM122734065 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.200G>A p.G67E 17:7674935-7674935 6
22 COSM144087276 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.367C>T p.R123W 17:7673776-7673776 6
23 COSM111758876 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.844C>T p.R282W 17:7673776-7673776 6
24 COSM142560107 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.479G>A p.G160E 17:7674935-7674935 6
25 COSM142563486 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.892C>T p.R298C 17:7670700-7670700 6
26 COSM105620035 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.659A>G p.Y220C 17:7674872-7674872 6
27 COSM143961018 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.358G>A p.G120R 17:7673785-7673785 6
28 COSM121896990 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.439G>A p.G147R 17:7673785-7673785 6
29 COSM142846793 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.845G>A p.R282Q 17:7673775-7673775 6
30 COSM143370725 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.479G>A p.G160E 17:7674935-7674935 6
31 COSM144134046 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.175G>A p.V59M 17:7674879-7674879 6
32 COSM111760509 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.1024C>T p.R342* 17:7670685-7670685 6
33 COSM111835509 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.965C>T p.P322L 17:7673563-7673563 6
34 COSM121938537 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.256G>A p.V86M 17:7674879-7674879 6
35 COSM144665820 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.728G>A p.R243Q 17:7673775-7673775 6
36 COSM144094943 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.295G>A p.E99K 17:7674191-7674191 6
37 COSM144090615 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.319G>A p.G107R 17:7673824-7673824 6
38 COSM144712053 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.535G>A p.V179M 17:7674879-7674879 6
39 COSM121953255 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.434G>A p.C145Y 17:7673790-7673790 6
40 COSM144087044 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.119G>A p.G40E 17:7674935-7674935 6
41 COSM142572611 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.728G>A p.R243Q 17:7673775-7673775 6
42 COSM143378316 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.542A>C p.Y181S 17:7674872-7674872 6
43 COSM144358367 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.535G>A p.V179M 17:7674879-7674879 6
44 COSM93243863 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.652G>A p.V218M 17:7674879-7674879 6
45 COSM144122349 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.278T>C p.L93P 17:7674208-7674208 6
46 COSM106124152 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.965C>T p.P322L 17:7673563-7673563 6
47 COSM111818396 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.652G>A p.V218M 17:7674879-7674879 6
48 COSM142841426 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.796G>A p.G266R 17:7673824-7673824 6
49 COSM142565177 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.679G>A p.G227R 17:7673824-7673824 6
50 COSM143948172 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.319G>A p.G107R 17:7673824-7673824 6

Expression for Primary Peritoneal Carcinoma

Search GEO for disease gene expression data for Primary Peritoneal Carcinoma.

Pathways for Primary Peritoneal Carcinoma

Pathways related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 VEGFA TP53 RET MUC16 IL10 IFNG
2
Show member pathways
13.47 VEGFA TP53 IL10 IFNG ERBB2 EGFR
3
Show member pathways
13.02 VEGFA TP53 RET IL10 IFNG ERBB2
4
Show member pathways
12.98 TP53 IL10 IFNG EGFR CXCL8 CXCL10
5
Show member pathways
12.75 VEGFA TP53 RET ERBB2 EGFR BRCA2
6
Show member pathways
12.62 TP53 PGR ERBB2 EGFR BRCA2 BRCA1
7
Show member pathways
12.59 TP53 ERBB2 EGFR BRCA2 BRCA1
8
Show member pathways
12.47 TP53 IL10 IFNG ERBB2 EGFR
9 12.44 TP53 ERCC1 BRCA2 BRCA1
10 12.29 VEGFA TP53 MIR195 ERBB2 EGFR BRCA1
11 12.25 VEGFA TP53 ERBB2 EGFR
12
Show member pathways
12.16 TP53 IL10 IFNG EGFR CXCL8
13 12.09 VEGFA TP53 IFNG EGFR
14 12.07 VEGFA RET IL10 CXCL8
15 11.99 VEGFA TP53 EGFR BRCA2 BRCA1
16 11.95 VEGFA TP53 RET IFNG ERBB2 EGFR
17 11.87 VEGFA TP53 IL10 CXCL8
18 11.83 VEGFA IFNG ERBB2 EGFR
19
Show member pathways
11.81 VEGFA ERBB2 EGFR
20 11.81 VEGFA IFNG CXCL8
21 11.8 ERCC1 BRCA2 BRCA1
22
Show member pathways
11.75 TP53 BRCA2 BRCA1
23 11.74 TP53 IFNG CXCL8
24 11.64 TP53 ERBB2 BRCA1
25 11.63 TP53 IFNG EGFR CXCL8 CXCL10
26 11.62 TP53 ERCC1 ERBB2 BRCA1
27
Show member pathways
11.61 VEGFA IFNG CXCL8
28 11.58 TP53 RET ERBB2 EGFR
29 11.54 IFNG CXCL8 BRCA1
30 11.49 TP53 IFNG EGFR
31 11.48 IL10 IFNG CXCL8
32 11.46 IL10 CXCL8 CXCL10
33 11.44 VEGFA RET EGFR
34 11.38 VEGFA TP53 CXCL8 BRCA1
35 11.22 VEGFA TP53 ERBB2 EGFR CXCL8
36 10.96 IL10 ERBB2 EGFR CXCL8 CXCL10

GO Terms for Primary Peritoneal Carcinoma

Biological processes related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.21 VEGFA RET PGR IL10 ERBB2 EGFR
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.07 VEGFA TP53 PGR IL10 EGFR CXCL10
3 positive regulation of cell proliferation GO:0008284 10.02 VEGFA IFNG ERBB2 EGFR CXCL10
4 positive regulation of transcription, DNA-templated GO:0045893 9.95 TP53 RET IL10 EGFR BRCA2 BRCA1
5 positive regulation of cell migration GO:0030335 9.9 VEGFA RET EGFR CXCL10
6 regulation of cell proliferation GO:0042127 9.88 TP53 EGFR CXCL10 BRCA1
7 positive regulation of protein phosphorylation GO:0001934 9.84 VEGFA IFNG ERBB2 EGFR
8 cytokine-mediated signaling pathway GO:0019221 9.83 VEGFA TP53 IL10 CXCL8 CXCL10
9 positive regulation of gene expression GO:0010628 9.8 VEGFA TP53 RET IFNG ERBB2 BRCA1
10 positive regulation of kinase activity GO:0033674 9.77 RET ERBB2 EGFR
11 positive regulation of epithelial cell proliferation GO:0050679 9.75 VEGFA ERBB2 EGFR
12 positive regulation of MAP kinase activity GO:0043406 9.74 VEGFA ERBB2 EGFR
13 nucleotide-excision repair GO:0006289 9.67 TP53 ERCC1 BRCA2
14 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.63 TP53 EGFR
15 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.63 MIR195 IL10
16 chromosome organization GO:0051276 9.63 TP53 ERCC1 BRCA2
17 response to molecule of bacterial origin GO:0002237 9.62 IL10 CXCL8
18 positive regulation of MHC class II biosynthetic process GO:0045348 9.61 IL10 IFNG
19 response to gamma radiation GO:0010332 9.58 TP53 CXCL10 BRCA2
20 negative regulation of ERBB signaling pathway GO:1901185 9.56 ERBB2 EGFR
21 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.55 VEGFA TP53
22 leukocyte chemotaxis GO:0030595 9.54 IL10 CXCL8 CXCL10
23 chordate embryonic development GO:0043009 9.51 BRCA2 BRCA1
24 double-strand break repair GO:0006302 9.46 TP53 ERCC1 BRCA2 BRCA1
25 response to X-ray GO:0010165 9.43 TP53 ERCC1 BRCA2
26 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.13 TP53 BRCA2 BRCA1
27 negative regulation of mitotic cell cycle GO:0045930 8.92 TP53 MIR195 IL10 EGFR

Molecular functions related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.7 VEGFA TP53 PGR ERBB2 EGFR BRCA2
2 protein phosphatase binding GO:0019903 9.5 TP53 ERBB2 EGFR
3 TFIID-class transcription factor complex binding GO:0001094 9.26 TP53 ERCC1
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 RET ERBB2 EGFR
5 cytokine activity GO:0005125 9.02 VEGFA IL10 IFNG CXCL8 CXCL10

Sources for Primary Peritoneal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....